Clinical significance of plasma anti-TOPO48 autoantibody and blood survivin-expressing circulating cancer cells in patients with early stage endometrial carcinoma
- 50 Downloads
To examine the clinical significance of an autoantibody (AAb) against a novel tumor-associated antigen (TAA) derived from human DNA-topoisomerase I, termed as TOPO48 AAb, and peripheral blood survivin-expressing circulating cells (CCC) in patients with early stage endometrial cancer (EC).
Blood samples were collected from 80 patients with early stage EC and 80 age-matched healthy subjects. Plasma levels of the TOPO48 AAb were measured with a specific antibody capture enzyme-linked immunosorbent assay (ELISA) and blood survivin-expressing CCC assessed with a reverse transcription-polymerase chain reaction products based on a hybridization-enzyme-linked immunosorbent assay (RT-PCR–ELISA). Sixty patients were followed up for 36 months after the initial assay test.
There were 75% and 60% samples with positive levels of the TOPO48 AAb and survivin-expressing CCC in the cancer patients, respectively. However, the cumulative positive rate of combination of the two markers was increased to 93.3% with 0.927 (95% CI 0.871–0.984) of area under the curve (AUC) in receiver operating characteristic (ROC) curve analysis. During the follow-up period, patients with positive TOPO48 AAb but negative surviving-expressing CCC had a higher survival rate and a longer survival time than those with negative AAb but positive CCC (P = 0.01).
The combination of TOPO48 AAb and survivin-expressing CCC may be used as a novel recipe to improve the efficiency of early diagnosis and provide more accurate prognostic prediction in patients with early stage EC.
KeywordsEndometrial carcinoma Early diagnosis Prognosis Anti-TOPO48 autoantibody Survivin-expressing circulating cancer cells
XHJ, ZYY and XH: data collection, experimental performs, data analysis, manuscript draft writing; KX and JZ: clinical patients and control support; JBZ, JC and MC: experimental support; SMY, project development, data collection, manuscript writing and review
This study was partially supported by Grant no. KJXM20030826 from the Research and Development Program of the Chengdu Technology Bureau, Chengdu, China, and partly supported by Sichuan Science and Technology Program (Grant no. 2018SZ0144,2016SZ0066, 2018SZ0284 and 2018FZ0043) and West China Second University Hospital of Sichuan University (Grant no. kx027).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in this study involving were in accordance with the ethical standards of the institutional research committee of the Sichuan Provincial People’s Hospital (No. 20070126,) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Availability of data and materials
We have full control of all primary data and that we agree to allow the Journal to review our data if requested.
- 3.Carlson MJ, Thiel KW, Leslie KK (2014) Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health 6:429–435Google Scholar
- 15.Zhou L, Dicker DT, Matthew E, El-Deiry WS, Alpaugh RK (2017) Circulating tumor cells silent predictors of metastasis. Research 14:6Google Scholar
- 17.Bogani G, Liu MC, Dowdy SC, Cliby WA, Kerr SE, Kalli KR, Kipp BR, Halling KC, Campion MB, Mariani A (2015) Detection of circulating tumor cells in high-risk endometrial cancer. Anticancer Res 35:683–687Google Scholar
- 22.Cao M, Yie SM, Wu SM, Chen S, Lou B, He X, Ye SR, Xie K, Rao L, Gao E, Ye NY (2009) Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis 26:751–758CrossRefGoogle Scholar
- 24.Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ (2015) Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther 14:2401–2408CrossRefGoogle Scholar
- 26.Steinbakk A, Malpica A, Slewa A, Skaland I, Gudlaugsson E, Janssen EA, Løvslett K, Fiane B, Kruse AJ, Feng W, Yinhua Y, Baak JP (2011) Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma. Mod Pathol 24:1262–1271CrossRefGoogle Scholar
- 31.Wilczyński M, Danielska J, Wilczyński J (2016) An update of the classical Bokhman’s dualistic model of endometrial cancer. Prz Menopauzalny. 15:63–68Google Scholar